Evaluation of the Efficacy of Platelets Treated With Pathogen Reduction Process

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

842 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-05-31

Study Completion Date

2016-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a multicentre, double-blind, randomized therapeutic trial.

The primary objective of this study is to evaluate non-inferiority with regard to prevention and control of haemorrhage:

* of platelet concentrates treated by pathogen reduction(Intercept amotosalen and UVA procedure)
* compared with the usual platelet concentrates (in additive solution intersol), reference arm, and
* compared with platelet concentrates re-suspended in autologous plasma (historic arm) These three products are available and authorised by ANSM (formerly AFSSAPS).

The secondary objectives is to evaluate the transfusion needs, transfusion outcomes and safety and the decreased frequency of grade 2 or higher side effects related to transfusion allergy to platelets.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pathogen Reduction Evaluation & Predictive Analytical Rating Score

NCT02783313

Thrombocytopenia

COMPLETED NA

Treatment of Thrombocytopenia in Patients With Chronic Liver DiseaseUndergoing an Elective Procedure

NCT01972529

Thrombocytopenia Associated With Liver Disease

COMPLETED PHASE3

Perioperative Eltrombopag in Patients With Inherited Thrombocytopenia

NCT03638817

Thrombocytopenia

COMPLETED PHASE2

AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy

NCT00102323

Thrombocytopenia Idiopathic Thrombocytopenic Purpura

COMPLETED PHASE3

Strategies for Transfusion of Platelets (SToP)

NCT00420914

Thrombocytopenia

TERMINATED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

There is an unresolved difficulty in the evaluation of haemorrhagic symptoms in thrombocytopenia due to the very nature of the scale, which is the international standard at this time (WHO scale). This scale is based on the level of blood loss and is applicable to any haemostasis disorder. We will keep it as the standard but have decided to be particularly rigorous in the data collection and will perform daily haemorrhagic assessment.

Several sequences of missing data can be imputed for one patient. Each sequence of missing data will be replaced if and only if the number of consecutive days missing does not exceed 15%\* of the total length of the patient's stay. If one sequence of missing data is longer than the 15%, no replacement will be done for the patient. (Example: If the total stay is 30 days, the maximal length of a missing data sequence accepted is 4 days). The following strategies will be used to replace missing data:

• The first observation is missing: Next observation carried backwards (NOCB) assigns the next known score after the missing value to the missing one.

• The last observation is missing: Last observation carried forward (LOCF) assigns the last known score before the missing value to the missing one. (Suppose that the situation is stable whilst the patient is leaving the hospital.)

• Sequence of one or several missing data with non-missing data before and after the sequence: Last and Next1 assigns the average of the person's last known and next known observation to the missing value. The score is rounded down to the nearest whole number if needed. (Ex mean (1+2) =1)

\* 15% rounded up to nearest whole number.

1 : Engels, J.M. 2003. Imputation of Missing Longitudinal Data : a Comparison of Methods. Journal of Clinical Epidemiology 56 (2003) 968-976

Following a quality analysis of EFFIPAP study's recruitment, it was decided by the sponsor to increase the number of patients. Approximatively thirty additional patients will be included in order to replace non analyzable patients for the following reasons : wrongly included, non-transfused patients, consent withdrawal. Those 30 additional patients will allow us to reach our initial target of 810 analyzable patients in order to respond to the main objective of the study

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aplasia With Expected Thrombocytopenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Historical control arm

Patients transfused with platelet concentrates re-suspended in autologous plasma

Group Type ACTIVE_COMPARATOR

Autologous plasma

Intervention Type BIOLOGICAL

Transfusions of platelet concentrates re-suspended in autologous plasma

Control arm

Patients transfused with platelets prepared in additive solution

Group Type ACTIVE_COMPARATOR

Additive solution

Intervention Type BIOLOGICAL

Transfusions of platelets prepared in additive solution (Intersol)

Experimental arm

Patients transfused with platelets treated by pathogen reduction process

Group Type EXPERIMENTAL

Pathogen reduction process

Intervention Type BIOLOGICAL

Patients transfused with platelets treated by pathogen reduction process

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Autologous plasma

Transfusions of platelet concentrates re-suspended in autologous plasma

Intervention Type BIOLOGICAL

Additive solution

Transfusions of platelets prepared in additive solution (Intersol)

Intervention Type BIOLOGICAL

Pathogen reduction process

Patients transfused with platelets treated by pathogen reduction process

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aged 18 years or older
* Patient hospitalised for bone marrow aplasia, with expected stay of over 10 days and in principle requiring platelet transfusion support (at least twice).
* Signed informed consent
* Patients with DIC can be included; they will undergo a separate analysis.
* A negative pregnancy test is necessary before inclusion in all women of childbearing age

Exclusion Criteria

* Patient included in this trial previously during a prior aplasia episode.
* Patient requiring curative anticoagulant treatment at the time of inclusion (vitamin K antagonists, heparin (LMWH and NFH), anti-IIa and Xa at curative doses for treatment or prophylaxis of arterial or venous thromboembolic disease (TED) or as part of the treatment for cardiac valvulopathy and complications of atrial fibrillation).
* Thrombocytopenia due to increased destruction
* Patient requires washed platelet concentrates (i.e., with residual plasma less than that remaining during the addition of an additive solution) due to previous intolerance to platelets (cf IgA deficiency, history of major allergic reaction)
* Patient requiring products "CMV negative " (previously included in a protocol transfusion CMV negative)
* Patients with platelet transfusion refractoriness during a previous period of cytopenia, including patient with platelet refractoriness related to an anti-HLA alloimmunization (thus, patient already known as requiring compatible platelets HLA)
* Patient who requires compatible HLA platelets due to a refractory state relative to anti-HLA alloimmunization
* Patient presenting a platelet transfusion refractoriness at the time of previous aplasia.
* Protected adults and persons deprived of liberty

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No